Serum levels of YKL-40 (Table 14) were independent of serum carcinoembryonic antigen (CEA) in CRC [188], serum cancer antigen 125 (CA-125) in ovarian cancer [191], serum human epidermal growth factor receptor 2 (HER-2) in metastatic breast cancer [190], serum lactate dehydrogenase (LDH) in small cell lung cancer [192], and serum prostate-specific antigen (PSA) in metastatic prostate cancer [208]. This evidence concerns the gene ERBB2 and ovarian cancer.